WO2019078662A2 - Tyrosinase inhibition and skin-whitening activity of desmodium sequax solvent extract or fraction thereof - Google Patents

Abstract

The present invention relates to a skin-whitening cosmetic composition, functional health food, quasi-drug composition, and pharmaceutical composition for preventing or treating diseases of hyperpigmentation containing a Desmodium sequax extract or a fraction thereof.

Description

Tyrosinase inhibition and whitening activity of desmodur squash solvent extract or its fractions

The present invention relates to a process for the preparation of Desmodium sequax wall extract or fractions thereof as an active ingredient, or a composition for preventing or treating dermatological pigmentary diseases.

The skin color of a person is genetically determined by the concentration and distribution of melanin in the skin, but is also influenced by environmental or physiological conditions such as sunlight, fatigue, and stress.

The chemical action of melanogenesis, which determines the color of skin, has been reported so far in various papers, etc. Melanocytes, which are melanocytes, secrete cells from ultraviolet light in melanosomes called intracellular organelles It is known that the melanin is transferred from melanocytes to keratinocytes. It has been reported that melanin transferred to keratinocytes determines skin color.

The precursor required for the melanin biosynthesis process is an amino acid called tyrosine. The tyrosine is converted into dihydroxyphenylalanine (DOPA), and then converted to melanin through a substance called dopaquinone .

In this regard, melanogenesis enzymes include tyrosinase (TYR), tyrosinase-related protein 1 (TRP-1) and tyrosinase-related protein 2 -2 / DOPA, chrome tautomerase), and the melanin-forming enzyme is known to be regulated by a transcription factor called MITF (microphthalmia-associated transcription factor). Tyrosinase, which plays an important role in the melanin synthesis pathway, converts L-tyrosine to L-DOPA (L-3,4-dihydroxyphenylalanine), rapidly converts the resulting L-DOPA to L-dopaquinone, The melanin is formed by various reactions of the melanin. Melanin synthesized by tyrosinase makes the skin darker. Studies on skin whitening method to suppress skin melanin synthesis and brighten skin color due to health or cosmetic demand are actively under way.

As commonly known as whitening components, arbutin of inhibiting tyrosinase activity, kojic acid (kojic acid), azelaic acid, aloe sour 4-butyl resorcinol, resveratrol, ceramides, seuping High-1-phosphate, seuping tympanic Force A substance such as polyquinoline, hydroquinone (Korean Patent Laid-Open Publication No. 2016-0014271), and the like. Such whitening ingredients are possible skin gwasaek small improvement in the chimchakjeung by inhibiting the synthesis of melanin, lightening the skin tone to achieve a skin-lightening or ultraviolet light, hormones, or the spots or freckles due to the dielectric and the like. However, some of the whitening ingredients have a problem in that when the skin is applied, the use amount is limited due to safety problems such as irritation and redness, or the effect is insignificant so that a substantial effect can not be expected. In particular, hydroquinone if the rain has been banned its use as an unwanted side effect replaced by the ^{(European Committee 24 th Dir 2000/} 6 / EC), hydroquinone arbutin structural analogs, such as bars, such as irreversible bleaching.

As described above, in the whitening field, it is important not only to have a whitening effect by having a tyrosinase inhibiting effect, but also to secure stability, and development of a substance that satisfies all of the above requirements is still required.

One object of the present invention is to provide a desmodium sequax wall extract or a fraction thereof as an active ingredient.

Another object of the present invention is to provide a health functional food for skin whitening comprising Desmoditic sputum extract or a fraction thereof as an active ingredient.

It is still another object of the present invention to provide a pharmaceutical composition for preventing or treating dermatological pigmentary diseases, which comprises desmoditic sputum extract or a fraction thereof as an active ingredient.

It is still another object of the present invention to provide a quasi-drug composition for skin whitening comprising Desmodium spuxus extract or a fraction thereof as an active ingredient.

It is a further object of the present invention to provide a skin whitening method comprising the step of administering a desmodur spsculus extract or a fraction thereof to a subject.

It is a further object of the present invention to provide a method for the prevention or treatment of dermatological pigmentary diseases, comprising the step of administering to the individual a Desmodur spsculus extract or a fraction thereof.

The composition of the present invention not only has a tyrosinase inhibitory effect and a melanin formation inhibitory effect but also has stability and can be safely and usefully used as a whitening composition or a therapeutic composition for skin hypercholesterolemia.

Figure 1 shows the tyrosinase inhibitory activity of the natural extract SD018 in the present invention.

Fig. 2 shows that the active fraction of the SD018 natural extract of the present invention is obtained by silica column chromatography.

FIG. 3 shows a pixel analysis for analyzing the inhibitory effect of melanin on the zebrafish embryo of the natural extract SD018 in the present invention.

FIG. 4 shows the inhibitory effect on melanin formation by zebrafish embryo of the natural extract SD018 in the present invention.

FIG. 5 shows the effect of inhibiting melanin formation by zebrafish fry of natural extract SD018 in the present invention.

Hereinafter, the present invention will be described in more detail.

On the other hand, each description and embodiment disclosed herein can be applied to each other description and embodiment. That is, all combinations of the various elements disclosed herein are within the scope of the present invention. In addition, it can not be said to the scope of the invention by the specific description will be described limits.

In addition, those of ordinary skill in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described in this application. Further, such equivalents are intended to be included in the present invention.

In order to solve the above problems, in one aspect, the present invention relates to a method for producing a desmodium sequax Wall extract or a fraction thereof as an active ingredient.

The term " desmodium " in the present invention is a genus belonging to the genus Fabaceae and distributed in the tropical and subtropical regions. Desmodium ( Desmodium) There are about 350 species including sequax . Mainly inconspicuous leguminous plants with bright colors and large flowers, used as green fertilizer, feed and some herbs.

In the present application it confirmed that des modium (Desmodium) even in holds a des modium seukeok Suga skin whitening effect, to retain stability.

The extract of Desmodur spscus herein comprises extracts of all the formulations which can be formed using extracts of the Desmodur spsculus extract of the present invention and its diluted solution, concentrate, dried product, adjusted product, purified product or mixture thereof.

In addition, the Desmodur spsculus extract may be produced by extracting from at least one of roots, stems, leaves or flowers of Desmodur spsc, but is not particularly limited thereto.

In addition, the Desmodurium spuxus extract of the present invention can be obtained from Desmodiums sp. By any method as long as it has a skin whitening effect or a preventive, ameliorative or therapeutic effect of a dermatological pigmentary disease, A cold extraction method in which Cux is immersed in a solvent and extraction is carried out at room temperature of 10 to 25 ° C, a heat extraction method in which the extraction is performed by heating at 40 to 100 ° C, an ultrasonic extraction method in which ultrasonic waves are extracted, and a reflux extraction method using a reflux condenser . These methods may be performed alone or in combination of two or more methods.

The kind of the extraction solvent used in the extraction of the present invention is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent of the present invention include water, a C1-4 alcohol, hexane, ethyl acetate, chloroform, dichloromethane and mixtures thereof And a solvent to be selected.

The term " fraction " as used herein refers to the result obtained by performing a fractionation to separate a specific component or a specific component group from a mixture containing various components.

The fractionation method for obtaining the fractions of the present invention is not particularly limited and may be carried out according to a method commonly used in the art. A solvent fractionation method performed by treating various solvents, an ultrafiltration fractionation method performed by passing through an ultrafiltration membrane having a constant molecular weight cut-off value, various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity ), A combination thereof, and the like.

The kind of the fraction solvent used to obtain the fraction of the present invention is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the fraction solvents herein include polar solvents such as water, alcohols (e.g., 1 to 4 carbon atoms); And non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of one or more.

The extract or fraction of Desmodur squash of the present invention is generally selected from the range of 0.000001 to 0.1 part by weight per 100 parts by weight based on the total weight of the composition of the present invention, but is not particularly limited thereto.

According to one embodiment of the present disclosure, the compositions herein may inhibit tyrosinase activity and / or inhibit melanin synthesis.

The term " skin whitening " in the present invention refers to brightening skin tone by inhibiting the synthesis of melanin pigment and / or inhibiting tyrosinase activity. The skin whitening may also include improving skin hyperpigmentation, such as sunburn, freckles, blotchiness, or melanoma due to ultraviolet light, hormones or heredity.

The cosmetic composition of the present invention may be in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, spray, And may be formulated and provided in a selected form.

The cosmetic composition of the present application may further comprise a cosmetically acceptable carrier.

The kind of the cosmetically acceptable carrier of the present invention is not particularly limited so long as it does not impair the activity and properties of the cosmetic composition of the present invention, and any cosmetically acceptable carrier conventionally used in the art can be used. Non-limiting examples of the cosmetically acceptable carrier include saline, sterilized water, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and the like. These may be used alone or in combination of two or more. The cosmetically acceptable carriers herein may comprise non-naturally occuring carriers.

The cosmetically acceptable carriers herein vary according to the formulation of the cosmetic composition.

When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, it is preferable to use an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc, zinc oxide May be used, but is not limited thereto.

When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or the like may be used as a carrier component. But are not limited to, propellants such as hydrocarbons, propane / butane or dimethyl ether.

When the formulation of the cosmetic composition of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent may be used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, Propylene glycol, 1,3-butyl glycol oil and the like can be used. Particularly, it is possible to use an oil such as cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or sorbitan Fatty acid esters can be used, but are not limited thereto.

When the formulation of the cosmetic composition of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester , Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, but are not limited thereto.

When the formulation of the cosmetic composition of the present invention is a soap, it is preferable to use, as a carrier component, an alkali metal salt of a fatty acid, a fatty acid hemiester salt, a fatty acid protein hydrolizate, isethionate, a lanolin derivative, an aliphatic alcohol, a vegetable oil, But is not limited thereto.

In the case where the formulation of the cosmetic composition of the present invention is a pack, a fill-off pack containing polyvinyl alcohol or the like, a wash-off pack containing a pigment such as kaolin, talc, zinc oxide, , Or a mask sheet pack, and is not particularly limited thereto.

The cosmetic composition of the present invention may further comprise components included in conventional skin external agent components such as water, a surfactant, a moisturizer, a lower alcohol, a chelating agent, a bactericide, an antioxidant, an antiseptic, a pigment and a fragrance.

Another aspect of the present invention is to provide a health functional food for skin whitening, which comprises Desmodur spsculus extract or a fraction thereof as an active ingredient.

The Desmodur spsculus extract or its fractions and whitening are as described above.

The term " health functional food " in the present invention refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and rings using raw materials and components having useful functions in the human body.

The term "functional" as used herein means that the structure and function of the human body have a beneficial effect on health uses such as controlling nutrients or physiological actions. The health functional food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients that are conventionally added in the art. In addition, the formulation of the dietary supplement is also formulated to be recognized as a dietary supplement can be made without limitation.

The health functional food of the present invention can be manufactured in various formulations, and unlike general pharmaceuticals, it has advantages in that it does not have side effects that may occur when a food is used as a raw material for a long period of time, and has excellent portability. of health food can be consumed as a supplement for enhancing the skin whitening effect.

The health functional food of the present invention may contain various flavors or natural carbohydrates as an additional ingredient. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau Martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.

In addition to the above, the health functional food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, protective colloid thickener, pH adjuster, stabilizer, preservative, glycerin, A carbonating agent used in a carbonated beverage, and the like. These components may be used independently or in combination. Although the proportion of such additives is not critical, it is generally selected from the range of 0.000001 to 0.1 part by weight per 100 parts by weight of the health food of the present invention, but is not particularly limited thereto.

Another aspect of the present invention is to provide a pharmaceutical composition for preventing or treating dermatological pigmentary diseases, which comprises Desmodur spsculus extract or a fraction thereof as an active ingredient.

The Desmodur spsculus extract or its fractions are as described above.

The term " dermatological pigmentary disease " in the present invention means a disease in which a coloring matter is excessively deposited on the skin. Specifically, the dermatological pigmentation disease can be spots, freckles, black spots, dull spots or melanomas.

The term " prevention " in the present invention means any action by which the composition of the present invention inhibits or delays the development of dermatological pigmentary diseases.

The term " treatment " in the present invention means any action which causes the pharmaceutical composition of the present invention to improve or alleviate the symptoms of dermatological pigmentary diseases.

In the present invention, the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier.

The term " pharmaceutically acceptable carrier " in the present invention refers to a carrier or diluent which does not irritate the organism and does not inhibit the activity or properties of the dermatological pigment disease symptom of the present invention. Examples of the pharmaceutical carrier which is acceptable for the composition to be formulated into a liquid solution include sterilization and sterilization which are suitable for a living body and include saline, sterilized water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol And one or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added.

In addition, pharmaceutically acceptable carriers of the present invention may include non-natural carrier.

The pharmaceutical compositions of the present invention may be administered in single or multiple doses in a pharmaceutically effective amount.

As used herein, the term " pharmaceutically effective amount " means an amount sufficient to prevent or treat a disease at a reasonable benefit / risk ratio applicable to medical prophylaxis or treatment, and the effective dose level will depend on the severity of the disease, , The body weight of the patient, the health, the sex, the sensitivity of the patient to the drug, the time of administration of the composition of the present invention, the route of administration and the rate of release, the duration of the treatment, And other factors well known in the medical arts.

Another aspect of the present invention is to provide a quasi-drug composition for skin whitening, which comprises Desmodur spsculus extract or a fraction thereof as an active ingredient.

The Desmodur spsculus extract or its fractions are as described above.

The term " quasi-drug " in the present invention refers to products which are used for diagnosis, treatment, improvement, alleviation, treatment or prevention of diseases of human beings or animals, Quasi-drugs are products that are used for the treatment and prevention of diseases of humans and animals, products that are mild or have no direct action on the human body.

The quasi-drug composition of the present invention can be manufactured in a form selected from the group consisting of a body cleanser, a foam, a soap, a mask, an ointment, a cream, a lotion, an essence and a spray, but is not limited thereto.

When the desmodium spuxus extract of the present invention or a fraction thereof is used as a quasi-drug additive, the desmodium spuxx extract of the present invention or a fraction thereof may be directly added, or may be used in combination with other quasi-drugs or quasi-drugs, Can be used.

In another aspect to accomplish the object of the present invention, the present invention provides a method for whitening skin comprising administering to the individual an extract of Desdodium sp., Or a fraction thereof.

In the method of whitening the skin of the present invention, the extract of Desdodium spus or its fractions and whitening are as described above.

The extract or fraction thereof of Desmodur spus herein may be administered to an individual in need thereof in an effective amount.

 The level of effective dose can be determined by a person skilled in the art on the basis of common sense to the extent that the desired skin whitening effect is exhibited.

In another aspect of the present invention, there is provided a method of preventing or treating a dermatological pigmentary disease comprising administering to a subject a desmodur spsculus extract or a fraction thereof.

The extract of Desdodium spus or its fractions and administration are as described above.

The extract or fraction thereof of Desmodur spus herein may be administered to an individual in need thereof in an effective amount.

 The level of effective dose can be determined by those skilled in the art on the basis of common sense to the extent that the effect of preventing or treating dermatological pigment diseases is exhibited.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are intended to illustrate the present invention, but the scope of the present invention is not limited thereto.

Example 1. Desmodium spuxes ( Desmodium Sequax  Wall extract

Desmodium sequax Wall was taken and dried at room temperature. The dried material was cut to a suitable size and pulverized using a blender mixer to obtain a pulverized material. In order to obtain the extract from the desmodur crushed product, Desmodur spsculus extract (SD018) was obtained according to the solvent conditions as follows.

10 g of desmoduric squash crushed product was suspended in 100 mL of 70% (v / v) methanol (HPLC grade, 99.9%) and stirred at room temperature for 24 hours. The extract was filtered using a filter paper (Whatman, No. 2), concentrated under reduced pressure using an evaporator, dispensed into each tube to a dry matter content of about 25 to 50 mg, completely dried under reduced pressure at 30 to 50 ° C Extracts were obtained and weighed.

To a Death modium's keokseu extract obtained as described above was designated as SD018.

Example 2. Analysis of tyrosinase inhibitory effect

In order to analyze the inhibitory effect of tyrosinase inhibition of desmoduric sputaceans extract, desmoduric sputum extract was prepared by dissolving L-tyrosine (Sigma) with L-DOPA (L-3,4 -dihydroxy phenylalanine. < / RTI >

For the tyrosinase inhibition assay for L-tyrosine, 120 μl of 0.1 M sodium phosphate buffer solution (pH 6.5), 20 μl of 1,000 unit / mL tyrosinase, and 20 μl of sample were added to each well of a 96-well microplate and incubated at room temperature for 10 minutes After the reaction, 40 μl of 1.5 mM L-tyrosine was added, and the absorbance was measured at 490 nm for 10 minutes at 25 ° C.

For the N-control, distilled water was used. For the positive control (P-control), kojic acid (Sigma) was assayed at 20 to 80 μM, and for the extract, SD018 was assayed at 20 to 80 μg / .

The tyrosinase activity of the positive control kojic acid (KA, Sigma) was 87.11 ± 2.60% (KA20, KA 20 μM), 58.65 ± 1.35% (KA40, KA 40 μM), 24.45 ± (SD40, SD018 40 μg / mL), and 42.24 ± 2.05% (SD80, SD018 80 μg, respectively) / mL). As a result, it was confirmed that the activity of tyrosinase using tyrosine as a substrate was significantly inhibited by each concentration (FIG. 1).

Further, on the basis of the result of analysis of the IC ₅₀ (half maximal inhibitory concentration) of the inhibitory effect of tyrosinase, kojic acid was 49.73 ± 1.26 μM, SD018 was calculated to be 70.72 ± 1.43 μg / mL (Table 1 ).

IC ₅₀ values for tyrosinase inhibitors

	Kojic acid (μM)	SD018 ([mu] g / mL)
IC 50	49.73 ± 1.26	70.72 + 1.43

Example  3. Through silica chromatography Desmodium Sparks  Acquisition of the extract fraction

Acetate fraction in order to secure and suspended in chloroform (HPLC grade) of silica (Merck) Resin 5g of 100mL, were charged to a chromatography column (Φ14.4 X h250mm). Death modium's keokseu extract (SD018) were suspended for about 75mg in 1mL chloroform (HPLC grade, 99.9%), was centrifuged at 13,000 g for 10 minutes and then loading the supernatant. Solvent in the mobile phase is chloroform: methanol 100: 0 (v / v) 0 from: a rate of 100 (v / v), flow rate was flowed at a flow rate of 0.5 per minute ~ 0.75mL. Each Fraction solvent was separated by 4mL per tube, <Example 2> and analyzing the fractions by tyrosinase inhibitory activity in the same way, chloroform: methanol 80:20 (v / v) fraction of the ratio 8, 9 , Fractions with high activity at 10 were obtained.

Fractions were obtained in the same manner as shown in Fig.

To via a silica gel column chromatography to analyze the amount of weight under reduced pressure to concentrate the separated fraction following, Example 2 and tyrosinase inhibition in the same way effect, we analyzed the IC ₅₀ value was diluted for each concentration of ( Table 2).

The IC ₅₀ values of the active fractions obtained using silica gel column chromatography

	SD018 ([mu] g / mL)	SD018_Si (μg / mL)
IC 50	70.72 + 1.43	9.72 + - 0.62

Example 4. Confirmation of inhibition of melanin synthesis and safety effect in a zebrafish model

Zebra fish (Danio rerio) used as an experimental animal was cultivated in a fish tank with a temperature of 28-29 at a suitable growth temperature. The zebrafish feed hatches the commercially available INVE artemia sycsts and brine shrimp, hatching 2-3 times a day, and the day and night cycle is controlled by the 10 hour cycle of 14 hours night . To get a zebrafish embryo, I put a pair of male and female into a special mating tub at 16-18 o'clock the previous day. In order to induce spawning, light was given the next morning to induce spawning to secure the embryo.

The collected embryos were transferred to a Petri dish and stored in 0.1% methylene blue solution to determine whether they were fertilized or not. Modified embryos not stained with methylene blue were selected and transferred to a zebrafish embryo culture medium containing 0.2 g / L sea salt (sigma). After the fertilization, the embryos generated at 9 hours were divided into three groups of negative embryos in each well of a 96-well microplate and divided into a negative control (NCtrl), a positive control (PCtrl) and an experimental group. The experiment was carried out in triplicate. The positive control group was an embryo culture medium, the positive control group 1 was an embryo culture medium containing 0.2 mM 1-phenyl-2-thyourea (PTU, Sigma), the positive control group 2 was an embryo culture medium containing 20 mM kojic acid (Sigma) In the positive control group 3, an embryo culture medium containing 20 mM arbutin (Sigma) and in Experiment Groups 1 and 2 were added with 200 μL / well of each embryo culture medium containing 100 to 200 mg / mL of each sample.

The embryonic developmental stages were observed during 9-57 hpf (hours post fertilization) using an Olympus SZ2-ILST (eXcope T1000 camera) stereomicroscope and an Optika XDS-2 (Optika 4083.13 HDMI Prof Camera) inverted microscope.

Securing an image of each embryo at 57hpf, and the image analysis tool image J to distinguish the degree of melanogenesis: utilizing (https.. // imagej nih gov ) software and analyzed the area of the melanin-producing region (Fig. 3 ).

(Fig. 4). In the control group, PTU treatment group was 12.82 +/- 7.33%, kojic acid treatment group was 63.79 +/- 23.96%, arbutin treatment group was 39.33 +/- 13.02%, and SD018 treatment group was 41.38 +/- 12.84% .

After 72 hpf, it was observed by removing the alumina membrane. As a result, it was confirmed that the SD018 treated group showed a melanin formation inhibitory effect similar to arbutin (FIG. 5).

Production Example 1 Preparation of beverages containing desmodur spuchs extract or fractions

A drink comprising the above Desmodur spsculus extract or a fraction isolated therefrom was prepared as follows.

(0.5 part by weight), oligosaccharide (3 parts by weight), salt (0.5 part by weight) and water (76 parts by weight) were mixed homogeneously with the desmodur sp. Extract or fractions separated therefrom, 121 to 145 占 폚), and the beverage was packed in a small container such as a glass bottle or a plastic bottle to prepare a beverage.

Manufacturing example  2. Desmodium Sparks  Extract or The fraction  Manufacture of cosmetics containing

Emulsifier type cosmetics were prepared with the compositions shown in Table 3 below. The manufacturing method is as follows.

1) A mixture of 1 to 10 raw materials was heated to 65 to 85 占 폚.

2) The raw material of 11 was added to the mixture of step 1).

3) The mixture of raw materials 12 to 14 was heated to 65 to 85 캜 to be completely dispersed.

4) The mixture of step 2) was gradually added to the mixture of step 3), and the mixture was emulsified at 7,000 to 12,000 rpm for 2 to 3 minutes.

5) The raw material of 15 was dissolved in a small amount of water and then added to the mixture of the step 4) and emulsified for 2 to 5 minutes.

6) The raw materials of 16 to 18 were each weighed, then put into the mixture of step 5) and further emulsified for 30 seconds.

7) The mixture of step 6) was degassed after emulsification and cooled to 25-35 ° C to prepare an emulsifier-type cosmetic.

Composition of Emulsifier Type for Cosmetic Production

Furtherance		Formulation 1	Formulation 2	Formulation 3
One	Stearic acid	0.3	0.3	0.3
2	Stearyl alcohol	0.2	0.2	0.2
3	Clicilyl monostearate	1.2	1.2	1.2
4	Polyoxyethylene sorbitan monooleate esters	2.2	2.2	2.2
5	Methyl paraoxybenzoate	0.1	0.1	0.1
6	P-hydroxybenzoic acid profile	0.05	0.05	0.05
7	Cetyl ethyl hexanoate	5	5	5
8	Triglyceride	2	2	2
9	Jojoba oil	5	5	5
10	Wax	0.4	1.0	2.0
11	Cyclomethicone	3	3	3
12	Purified water	<100	<100	<100
13	glycerin	5	5	5
14	Triethanolamine	0.15	0.15	0.15
15	Polyacrylic acid polymer	0.12	0.12	0.12
16	Pigment	0.0001	0.0001	0.0001
17	incense	0.10	0.10	0.10
18	SD018 extract or fraction	0.00001	0.0001	0.001

From the above description, it will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. In this regard, it should be understood that the above-described embodiments are to be considered in all respects as illustrative and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention without departing from the scope of the present invention as defined by the appended claims.

Claims (10)

1. Desmodium sequax wall extract or fractions thereof as an active ingredient.
2. The cosmetic composition for skin whitening according to claim 1, wherein the desmodur skin extract is prepared by extracting desmodur skin with a solvent selected from the group consisting of water, an alcohol having 1 to 4 carbon atoms and a mixed solvent thereof .
3. The cosmetic composition for skin whitening according to claim 1, wherein the Desmodur spsculus extract is prepared by extracting from at least one of roots, stems, leaves and flowers of Desmodur sp.
4. The cosmetic composition for skin whitening according to claim 1, wherein the composition is intended to prevent or improve at least one selected from the group consisting of spots, freckles, black spots and dull spots.
5. A health functional food for skin whitening comprising desmodur squamous extract or a fraction thereof as an active ingredient.
6. A pharmaceutical composition for the prevention or treatment of dermatological pigmentary diseases, comprising an extract of Desmodur sp. Or a fraction thereof as an active ingredient.
7. [Claim 7] The pharmaceutical composition according to claim 6, wherein the dermatological pigmentary disease is spots, freckles, black spots, dull spots or melanomas.
8. A quasi-drug composition for skin whitening comprising desmoditic sputum extract or a fraction thereof as an active ingredient.
9. A method for skin whitening comprising the step of administering to a subject a desmodur sputum extract or a fraction thereof.
10. A method for preventing or treating a dermatological pigmentary disease, comprising administering to the individual a desmodur sputum extract or a fraction thereof.

Images